NCI Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0 June 17, 2022Vol.48 No.24By Alice Tracey
Trials & Tribulations ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV June 17, 2022Vol.48 No.24By Joel M. Palefsky and Robert Yarchoan
Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care June 10, 2022Vol.48 No.23By Alice Tracey
Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure May 27, 2022Vol.48 No.21By Paul Goldberg
Capitol Hill Cancer groups ask for $4.1 billion increase for NIH, $850 million boost for NCI in FY23 May 27, 2022Vol.48 No.21By Alice Tracey
Clinical Roundup NCI study: Cancer death rates among Black people have declined, but disparities remain May 20, 2022Vol.48 No.20
Capitol Hill Bipartisan misgivings: House appropriators chafe at Biden’s proposal to fund ARPA-H at the expense of NIH May 13, 2022Vol.48 No.19By Alice Tracey
Capitol Hill Whither ARPA-H? What can Biden’s agency do that cancer centers can’t? May 06, 2022Vol.48 No.18By Paul Goldberg
Drugs & Targets Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines April 29, 2022Vol.48 No.17
Conversation with The Cancer LetterFree Ned Sharpless steps down as NCI director April 08, 2022Vol.48 No.14By Matthew Bin Han Ong and Paul Goldberg
